SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 14511467.
  • 2
    Ligibel J, Winer E. Clinical differences among the aromatase inhibitors. Clin Cancer Res. 2003; 9: 473S479S.
  • 3
    Smith I, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003; 348: 24312442.
  • 4
    Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003; 98: 18021810.
  • 5
    Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 21312139.
  • 6
    Winer E, Hudis C, Burstein H, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status Report 2002. J Clin Oncol. 2002; 20: 33173327.
  • 7
    Winer E, Hudis C, Burstein H, et al. American Society of Clinical Oncology Technology Assessment Working Group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003; 21: 25972599.
  • 8
    Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992; 339: 115.
  • 9
    Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996; 348: 11891196.
  • 10
    Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983; 3: 419458.
  • 11
    Harvard School of Public Health. The CEA registry: standardizing the methods and practices of cost-effectiveness analysis [database online]. Available from URL: http://www.hsph.harvard.edu/cearegistry [accessed Jan 10, 2004].
  • 12
    Arias E. United States life tables, 2000. Natl Vital Stat Rep. 2002; 51: 138.
  • 13
    Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
  • 14
    Hillner B, Smith T. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med. 1991; 324: 160168.
  • 15
    Mahadevia P, Fleisher L, Frick K, Eng J, Goodman S, Powe N. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003; 289: 313322.
  • 16
    Lee J, Glick H, Hayman J, Solin L. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol. 2002; 20: 27132725.
  • 17
    Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis (2nd edition). New York: Oxford University Press, 2000.
  • 18
    Drugstore.com, Inc. Drugstore.com [pharmaceutical vendor online]. Available from URL: http://www.drugstore.com [accessed Jan 13, 2004].
  • 19
    British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary [database online]. Available from URL: http://www.bnf.org [accessed Jan 13, 2004].
  • 20
    Rx of Canada, LLC. Rx-Canada.com [pharmaceutical vendor online]. Available from URL: http://www.rx-canada.com [accessed Jan 13, 2004].
  • 21
    Hayman J, Hillner B, Harris J, Weeks J. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol. 1998; 16: 10221029.
  • 22
    Hayman J, Hillner B, Harris J, Pierce L, Weeks J. Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer. J Clin Oncol. 2000; 18: 287295.
  • 23
    Wai E, Trevisan C, Taylor S, Mates D, Jackson J, Olivotto I. Health system costs of metastatic breast cancer. Breast Cancer Res Treat. 2001; 65: 233240.
  • 24
    Chang J, Clark G, Allred D, Mohsin S, Chamness G, Elledge R. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003; 97: 545553.
  • 25
    Ray N, Chan J, Thamer M, Melton L. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997; 12: 2435.
  • 26
    Wiktorowicz M, Goeree R, Papaioannou A, Adachi J, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int. 2001; 12: 271278.
  • 27
    De Laet C, van Hout B, Burger H, Weel A, Hofman A, Pols H. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam Study. Osteoporos Int 1999; 10: 6672.
  • 28
    Haentjens P, Autier P, Barette M, Boonen S. The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg Am. 2001; 83-A: 493500.
  • 29
    Gould M, Dembitzer A, Sanders G, Garber A. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999; 130: 789799.
  • 30
    Sainsbury R. Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: a safety update from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial [abstract]. Presented at the Twenty-Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 11–14, 2002.
  • 31
    Howell A. An assessment of fracture rates over time (between 6 and 48 months) in the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial [abstract]. Presented at ECCO 12—The European Cancer Conference, Copenhagen, Denmark, September 21–25, 2003.
  • 32
    Eastell R. Effect of anastrozole on bone density and bone turnover: results of the ‘Arimidex’ (anastrozole), Tamoxifen Alone or in Combination (ATAC) trial bone sub-protocol. Presented at the Twenty-Fifth Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, Minnesota, September 19–23, 2002.
  • 33
    Kanis J, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby A. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002; 17: 12371244.
  • 34
    Hillner B, Hollenberg J, Pauker S. Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med. 1986; 80: 11151127.
  • 35
    Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Jarvinen M. Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet. 1999; 353: 802805.
  • 36
    Eifel P, Axelson J, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001; 93: 979989.
  • 37
    Goldhirsch A, Glick J, Gelber R, Coates A, Senn H. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001; 19: 38173827.
  • 38
    Ingle J. Adjuvant endocrine therapy in postmenopausal breast cancer. Clin Cancer Res. 2003; 9: 480S485S.
  • 39
    Buzdar A. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer—updated efficacy results based on a median follow-up of 47 months [abstract]. Breast Cancer Res Treat. 2003; 77: 295.
  • 40
    Hunink MG, Weeks JC, Pliskin JS, Elstein AS, Weinstein M. Decision making in health and medicine. Cambridge, UK: Cambridge University Press, 2001.
  • 41
    Coombes R, Hall E, Gibson L, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092.
  • 42
    Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349: 17931802.
  • 43
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. 1992;146: 473481.
  • 44
    Smith R, Cokkinides V, Eyre H. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003; 53: 2743.
  • 45
    Reid I, Brown J, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002; 346: 653661.
  • 46
    Hillner B, Ingle J, Chelbowski R, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003; 21: 40424057.
  • 47
    Gamel JW, Bonadonna G, Valagussa P, Edwards MJ. Refined measurement of outcome for adjuvant breast carcinoma therapy. Cancer. 2003; 97: 11391146.
  • 48
    Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001; 358: 277286.
  • 49
    Cole BF, Gelber RD, Goldhirsch A. A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group. Stat Med. 1995; 14: 17711784.